Cite
HARVARD Citation
Mansour, S. et al. (2021). Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study. British journal of ophthalmology. 105 (3), pp. 414-419. [Online].